GH Research PLC (GHRS)
NASDAQ: GHRS · Real-Time Price · USD
14.06
+1.03 (7.90%)
At close: Mar 31, 2026, 4:00 PM EDT
14.31
+0.25 (1.78%)
Pre-market: Apr 1, 2026, 7:48 AM EDT
GH Research Market Cap
GH Research has a market cap or net worth of $872.13 million as of April 1, 2026. Its market cap has increased by 27.82% in one year.
Market Cap
872.13M
Enterprise Value
591.94M
1-Year Change
27.82%
Ranking
Category
Stock Price
$14.06
Market Cap Chart
Since the IPO on June 25, 2021, GH Research's market cap has increased from $808.33M to $872.13M, an increase of 7.89%. That is a compound annual growth rate of 1.61%.
Market Cap History
| Date | Market Cap | % Change |
|---|---|---|
| Mar 30, 2026 | 808.24M | 2.60% |
| Dec 31, 2025 | 787.77M | 116.30% |
| Dec 31, 2024 | 364.20M | 20.71% |
| Dec 29, 2023 | 301.72M | -40.33% |
| Dec 30, 2022 | 505.64M | -58.34% |
| Dec 31, 2021 | 1.21B | 50.14% |
| Jun 25, 2021 | 808.33M | - |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
| Company | Market Cap |
|---|---|
| Arbutus Biopharma | 840.56M |
| Xencor | 832.39M |
| Phathom Pharmaceuticals | 829.75M |
| Fortrea Holdings | 829.35M |
| UroGen Pharma | 827.60M |
| MapLight Therapeutics | 823.69M |
| Cullinan Therapeutics | 812.26M |
| Janux Therapeutics | 792.64M |